Thrive led. Again. For the second time in recent cycles, Thrive Capital is reportedly anchoring a frontier AI round, this time in life sciences, not enterprise software. TechFundingNews reports that Isomorphic Labs is in advanced talks for a Series B exceeding $2 billion, with Alphabet, Isomorphic’s parent company, participating alongside Thrive. The round isn’t confirmed as closed. “In talks” is the operative phrase, and it matters: until signatures are on term sheets, the structure can change.
What is confirmed: Isomorphic Labs is real, its technology is established, and its commercial traction has evidence. The company is a DeepMind spinout built around AlphaFold3, the molecular modeling system Google DeepMind released in May 2024. AlphaFold3 represents a genuine technical milestone, it extended the original AlphaFold architecture to model interactions between proteins, DNA, RNA, and small molecules, which is the foundational capability for AI-driven drug discovery. This isn’t a paper company chasing a funding narrative. The science is documented and public.
The commercial proof points carry a qualifier. Isomorphic has disclosed partnerships with Eli Lilly and Johnson & Johnson with potential combined value reported at up to $1.7 billion. “Up to” is a term of art in pharma deal reporting. These structures typically involve an upfront payment plus milestone-contingent tranches, regulatory approvals, clinical trial outcomes, commercialization targets. The $1.7 billion figure almost certainly represents the total deal value if all milestones are achieved, not the guaranteed realized revenue. Lilly and J&J didn’t write a $1.7 billion check. They made commitments with conditions. That distinction matters for how you read the Series B context.
If the round closes at $2 billion-plus, Isomorphic would rank among the most heavily funded AI drug discovery companies globally. The prior reference point is Recursion Pharmaceuticals, which has raised approximately $1.3 billion cumulatively through multiple rounds. A single $2 billion Series B would exceed that cumulative total. This isn’t a routine biotech round, it’s a statement about what institutional investors believe AI-native drug discovery is worth at commercialization stage, not proof-of-concept stage.
The investor composition signals something else. Alphabet participating in its own spinout’s Series B isn’t unusual, it protects ownership and signals continued belief in the technology. Thrive leading is the notable element. Thrive’s recent portfolio positioning has emphasized companies with durable revenue foundations and defensible technology moats. Isomorphic has both, or will have, if the pharma milestones convert. Thrive’s reported lead is a validation signal for the commercial thesis, not just the science.
What to Watch
What to watch
Bloomberg confirmation is the threshold event. When a round of this size has two named investors and a financial figure, Bloomberg confirmation typically arrives within one cycle – either confirming the structure or reporting a revised figure. Watch for a formal Bloomberg or Reuters confirmation in the next 48-72 hours. If it arrives with a higher figure than $2 billion, the milestone-contingent pharma revenue is likely converting faster than the market currently expects. That’s the testable prediction: confirmation round size above $2.5 billion implies strong early milestone performance on the Lilly or J&J deals.